Colorectal Cancer

Advanced Colorectal Cancer with Marwan G. Fakih, MD

Mikhail Fedyanin, MD, medical oncologist, Russian Academy of Medical Sciences, Moscow, discusses some of the factors associated with discordance in mutation status in metastatic colorectal cancer during the 2016 ESMO Congress.

Advanced Colorectal Cancer with Michael Morse, MD

Advanced Colorectal Cancer with Michael Morse, MD

A genetic understanding of dMMR in rectal cancer could lead the way to precision medicine for these subgroups of patients

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses the need for better surrogate parameters for overall survival in colorectal cancer.

According to findings of a recent study, obesity is more prevalent in cancer survivors, specifically in those with a history of breast or colorectal cancer (CRC), compared with those without any history of disease.

Axel Grothey, MD, medical oncologist, Department of Oncology, Mayo Clinic, discusses the role of sidedness in tumor location in colorectal cancer.

Combined inhibition of the PD-L1/PD-1 axis with atezolizumab (Tecentriq) and the MEK pathway with cobimetinib (Cotellic) showed promising clinical activity and a good safety profile in heavily pretreated patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC), according to findings from a phase 1b study presented at the 2016 World Congress on Gastrointestinal Cancer.

MABp1 (Xilonix), a novel anti–interleukin 1-alpha (IL-1α) antibody, was safe and well tolerated, and demonstrated a significant impact on symptoms, compared with placebo, for patients with advanced colorectal cancer (CRC), according to findings from a phase III study presented at the 2016 World Congress of Gastrointestinal Cancer.

Colorectal cancer mortality rates have been on the decline in California for both men and women since the mid-1990s, but for Hispanic men, rates have remained essentially unchanged.

Kanwal Raghav, MBBS, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical application of the data on HER2 gene amplification in patients with metastatic colorectal cancer, as well as the benefits of using a therapy that combines trastuzumab and pertuzumab.

Early tumor shrinkage is linked to overall survival and could be a stronger surrogate marker than progression-free survival in metastatic colorectal cancer.

Matthew Yurgelun, MD, instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the prevalence of germline cancer susceptibility gene mutations in patients with colorectal cancer, as well as the next steps in identifying these mutations.

Liver metastases have long led to a poor diagnosis for patients with metastatic colorectal cancer (mCRC), especially when the metastases are unresectable. However, an increasing number of adjunct techniques can treat the liver until surgery becomes possible, and there are also alternatives to surgery for nonresectable patients.

Nintedanib may be a promising treatment option for patients with metastatic colorectal cancer who are not responding to treatment.